Despite a pressing need for money after its $58 billion Shire acquisition and an industrywide exodus from consumer health, Takeda CEO Christophe Weber said the company is unlikely to sell its Japanese over-the-counter unit. More: Takeda to keep consumer business,
read moreEli Lilly will buy Loxo for $235 per share in cash—a 68% premium over Loxo’s most recent closing price. Announced as JPM kicked off, the deal gives Lilly the high-priced TRK inhibitor Vitrakvi and three other targeted cancer drugs. More:
read moreLong-awaited details of the NHS Long Term Plan, which is to be funded by a government investment of £20.5 billion a year in real terms by 2023/24 – have now been unveiled, with the promise of saving almost half a
read moreJanssen has submitted an application to the European Medicines Agency (EMA) seeking to expand the approval of Stelara to include the treatment of adults with moderately to severely active ulcerative colitis (UC). More: Janssen files Stelara in Europe for ulcerative
read moreAn Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 – a potential treatment for Epidermolysis Bullosa (EB) – should continue, raising hopes for a new therapy for the condition. More: Green light
read moreA surge in cell and gene therapy trials – an increase of 37% since 2017 – highlights the UK’s leading position as a developmental hub in the sector, says the Cell and Gene Therapy Catapult. More: UK surge in cell
read more© 1994 - 2026 B.M. Pharmaceuticals